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We have read with interest the recent publication of Hegyi and Sahin-Tóth1 reporting that 
chronic pancreatitis (CP)-predisposing CPA1 mutations function through the misfolding 
pathway rather than through loss of CPA1 protein/activity. Herein, we explore an additional 
insight gleaned from this study beyond those discussed in an accompanying Editorial.2.  
In the original study reporting the association of CPA1 variants with CP, all unambiguous 
loss-of-function (LoF) variants (e.g., nonsense mutations) were lumped together with 
missense mutations that functionally impaired the CPA1 protein.3 However, unlike missense 
mutations, unambiguous LoF variants often result in transcripts that contain premature 
termination codons (PTC) and are thus prone to nonsense-mediated RNA decay (NMD). 
NMD detects and degrades PTC-containing transcripts, thereby preventing the accumulation 
of truncated proteins.4,5 This implies that most unambiguous LoF CPA1 variants would not be 
able to elicit ER stress and hence, in the light of the Hegyi and Sahin-Tóth study, will not 
predispose to CP. Indeed, the most frequently observed LoF variant, c.79C>T (p.Arg27*), 
was present at a lower frequency in European CP patients than in controls (Table 1). 
Additionally, we evaluated the pLI score for CPA1 in the Genome Aggregation Database 
(genomAD; http://gnomad.broadinstitute.org/). The pLI score indicates the probability that a 
gene is intolerant to heterozygous LoF variants, ranging from 0 (completely tolerated) to 1.0 
(extremely intolerant).6 The pLI score for CPA1 is 0. For the sake of comparison, PRSS1 and 
SPINK1 have pLI scores of 0 and 0.33 respectively; unambiguous LoF variants in the PRSS1 
gene actually protect against CP whereas unambiguous LoF variants in the SPINK1 gene 
predispose to CP.7 
Of the CPA1 variants so far reported,8 five may be regarded as unambiguous LoF variants 
by virtue of their mutation type and location (Table 1). We surveyed the clinical significance 
of these five LoF variants8. It would appear that only the classification of c.79C>T 
(p.Arg27*) as benign is strongly supported by genetic epidemiological data (Table 1). In 
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order to investigate the classifications of these five variants from a mechanistic standpoint, 
we tested whether the three coding variants that were predicted to generate PTCs, c.79C>T 
(p.Arg27*), c.357C>A (p.Tyr119*) and c.954_955delCA (p.Tys318*), would generate 
mutant transcripts that would be degraded by the NMD pathway. This was found to be the 
case for all three variants (figure 1). We also elucidated the precise splicing consequences of 
the two splice site mutations (i.e., c.148-1G>A and c.1072+1G>T) in a minigene system (see 
online supplementary figure S1); both  gave rise to transcripts that were prone to NMD. All 
experimental details are described in online supplementary material, table S1 and figures S2 
and S3. 
In summary, prompted by the recent Hegyi and Sahin-Tóth study,1 we provide evidence 
to suggest that most of the unambiguous LoF CPA1 variants reported to date may not 
predispose to CP. Following the same line of reasoning, some of the previously characterized 
LoF CPA1 missense mutations2 may also not predispose to CP. In other words, the pathology 
may be confined to a small subset of CPA1 mutations that are capable of eliciting ER stress. 
This may help to explain why rare functionally defective CPA1 variants were not found to be 
associated with CP in a large Chinese cohort study.9 
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FIGURE LEGEND 
Figure 1  Quantitative reverse transcriptase-PCR analysis of HEK293T cells transfected with 
CPA1 cDNA expression constructs carrying respectively the wild-type and variant sequences. 
(A) mRNA expression levels of the three variant sequences relative to that of the wild-type 
sequence. (B) Relative mRNA expression levels of the variant sequences in transfected cells 
with (grey) and without (black) cycloheximide (an NMD inhibitor) treatment. 
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Table 1   The five unambiguous LoF CPA1 variants discussed in this study 
Region Nucleotide 
change 
Amino acid change Cases (%) 
(n=1544)a 
Controls (%) 
(n=6370)b 
Current 
classification 
of clinical  
significance8 
Functional analysis findings (this study) 
Exon 2 c.79C>T 
 
p.Arg27* 1 (0.06) 7 (0.11) Benign mRNA expression analysis 
demonstrated that the mutant transcript 
was subject to NMD. 
Intron 2 c.148-1G>A 
 
p.Leu50Hisfs*16 
(previously termed 
p.Leu50_Glu127del)2 
0 (0) 1 (0.02) Likely 
pathogenic 
Minigene splicing analysis revealed that 
the mutation primarily activated a 
cryptic 3'-splice site located 63 bp 
downstream of the normal one, resulting 
in the loss of the first 65 bp of exon 3 
from the transcript. This would lead to a 
frameshift starting at amino acid 
position 50, with the new reading frame 
ending in a stop at position 16. 
Exon 3 c.357C>Ac p.Tyr119* – – Uncertain mRNA expression analysis 
demonstrated that the mutant transcript 
was subject to NMD. 
Exon 8 c.954_955delCA p.Tyr318* 2 (0.13) 0 (0) Pathogenic mRNA expression analysis 
demonstrated that the mutant transcript 
was subject to NMD. 
Intron 9 c.1072+1G>T p.Asp330Ilefs*51 0 (0) 1 (0.02) Likely 
pathogenic 
Minigene splicing analysis confirmed 
that exon 9 was skipped. This would 
lead to a frame-shifting change starting 
at amino acid positon 330, with the new 
reading frame ending in a stop at 
position 51.  
a,bCombined European data from reference 2 unless otherwise specified. 
cDetected in a pancreatic cancer patient.10 
